Emmaus Life Sciences Q2 net revenue down 48% to $2.8M; net loss narrows to $1.1M

Emmaus Life Sciences, Inc.

2025-Q2 EPS reported -$0.05 revenue$5,223,000

Net revenue $2.8M, down 48% YoY from $5.4M; competition from generic L-Glutamine cited.
Loss from operations $0.4M vs income of $0.6M in prior year.
Net loss $1.1M ($0.02/share) vs $2.2M ($0.03/share) in Q2 2024; decrease due to lower other expense.
Cash balance $0.9M at June 30, 2025, down from $1.4M at year-end 2024.
Operating expenses reduced 33% to $3.0M, primarily from headcount reduction in Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.